Immunohistochemistry with monoclonal antibodies in peruvian indigenous with breast cancer, to forecast Global Survival

Stern, M., )ejerman, L., Das, R., Setiawan, :., Cruz-Correa, M., Perez, E., et al. Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry. Current Epidemiology Reports. 2016, 3: 181–190. https://doi.org/ 10.1007/s40471-016-0083-7

World Health Organization, International Agency for Research on Cancer (IARC) Source: Globocan 2020. Available from: https: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf [Accessed 20 January 2021].

Marker, K., Zavala, V., Vidaurre, T., Lott, P., Navarro, J., Casavilca, S., et al. Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. Cancer Res, 2020; 80 (9): 1893–1901. https://doi.org/10.1158/0008-5472.CAN-19-3659

Goud, K., Dayakar, S., Vijayalaxmi, K., Jangu, S., Reddy, A. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) Áuorescence in-situ hybridization (FISH) assay. Indian J Med Res. 2012, 135 (3): 312²317. Available from: http://www.ijmr.org.in/text.asp?2012/135/3/312/95605 [Accessed June 02, 2020].

Akram, M., Iqbal, M., Daniyal, M., Khan, A. Awareness and current knowledge of breast cancer. Biological Research. 2017, 50 (1): 33-53. https://doi.org/10.1186/s40659-017-0140-9

Hortobagyi G, Connolly J, D’Orsi C, Giuliano A, Edge S, Mittendorf E, et al. Breast. American Joint Committee on Cancer. AJCC cancer staging manual. 8th edition. New York: Springer. 2017. p. 589²636. Available from: https://cancerstaging.org/references-tools/Deskreferences/Documents/AJCC%208th%20Edition%20Breast%20 Cancer%20Staging%20System.pdf.[Accessed 20 January 2020].

Gamarra-Manrique R. Principio de Origen del Cáncer: Filogenia Molecular. First edition, Dinamarca, Copenhague, Ed. Aleph S.R.L., 2019.

Wolff, AC., Hammond, M., Allison, K., Harvey, B., Mangu, P., Bartlett, H., et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018, 36 (20): 2105-2122. https://doi.org/10.1200/-CO.2018.77.8738

Liu, Z., Wang, K., Lin, D., Xu, J., Chen, J., Long, X., et al. Impact of the updated 2018. ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases. Breast Cancer Res Treat. 2019, 175 (1): 51-57. https://doi.org/10.1007/s10549-019-05148-5

Wasserman, B., Carvajal-Hausdorf, D., Ho, .., :ong, :., Wu, N., Chu, V., et al. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, Áuorescence in situ hybridization, and quantitative immunoÁuorescence. Lab Invest. 2017, 97 (12): 1521²1526. https://doi.org/10.1038/labinvest.2017.93

Swain, S., Baselga, J., Kim, S., Ro, J., Semiglazov, V. Campone, M., et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive metastatic breast cancer. N Engl - Med. 2015, 372 (8): 724-734. https://doi.org/10.1056/NEJMoa1413513

Bilous, M., Morey, A., Armes, J., Bell, R., Button, P., Cummings M., et al. Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Res Treat. 2012, 134 (2): 617²624. https://doi.org/10.1007/s10549-012-2093-6

Meléndez R, and Asencio A, Factores clinicopatológicos asociados a la amplificación del gen HER2/neu en pacientes con cáncer de mama HER2/NEU (positivos). Anales de la Facultad de medicina. 2017, 78 (4): 381-385. https://doi.org/10.15381/anales.v78i4.14257

Telli, M., Chang, E., Kurian, A., Keegan, T., McClure, L., Lichtensztajn, D., et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011, 127 (2): 471-8. https://doi.org/10.1007/s10549-010-1173-8

Medina G. Características clínicas y pronósticas de los subtipos moleculares de cáncer de mama determinados por inmunohistoquímica, Arequipa, Perú. Rev. perú. med. exp. salud public, 2017, 34 (3): 472-477. https://doi.org/10.17843/rpmesp.2017.343.2530

Prieto A. Cáncer de mama: tratamientos inmunológicos. Clinica. 2014. 27: 33-41. https://doi.org/10.24197/cl.27.2019.33-41

Ramírez, V., García, G., Lores, C., Sánchez Y., Márquez, C. Histological and immunohistochemistry of invasive breast cancer in Pinar del Río province. Revista de Ciencias Médicas; 2019, 23 (1): 71-78. Available from: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/3801

Zeng X, Liang Z, Wu S. HER2 status in breast cancer of Chinese women: a study of 1170 cases using Áuorescence in-situ hybridization. Chinese Journal of Pathology. 2006, 35 (10): 584-588. https://doi.org/10.3760/j.issn:0529-5807.2006.10.003

Ferrando, J., Paléncia, L., Gotsens, M., Puig-Barrachina, V., Marí-Dell’Olmo, M., Rodríguez, M., al. Trends in cancer mortality in Spain: the inÁuence of the financial crisis. Gac Sanit. 2019, 33 (3): 229-234. https://doi.org/10.1016/j.gaceta.2017.11.008

Montoya, M., Gómez, W., Sánchez, J., García, H. Características y supervivencia de pacientes con cáncer de seno metastásico HER2-positivo en la era post-trastuzumab. Rev colomb. cancerol. 2018, 22 (3): 112-118. https://doi.org/10.1016/j.rccan.2018.09.002

Kaczmarek, E., Saint-Martin, C., Pierga, J., Brain, E., R Rouzier, R., Savignoni, A., et al. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database. Breast Cancer Res Treat. 2019, 178 (3): 505²512. https://doi.org/10.1007/s10549-019-05423-5

Mohar, A., Alvarado, A., Torres, J., Cabrera, P., Lara-Medina F. , Vi l l a r r e a l Y. , e t a l . F a c t o r e s p r o n ó s t i c o s e n p a c i e n t e s c o n cáncer de mama y metástasis cerebral como primer sitio de recurrencia. Salud Pública Méx, 2018, 60 (2): 141-150. https://doi.org/10.21149/9082

Daniels, J., Lord, S., Kiely, B., Houssami, N., Haywood, P. , L u , C . , e t a l . U s e a n d o u t c o m e s o f t a r g e t e d t h e r a p i e s i n early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. British Medical -ournal. 2017, 7 (1): e014439. https://doi.org/10.1136/bmjopen-2016-014439

Mimica, X., Acevedo, F., Oddo, D., Ibáñez, C., Medina, L., Kalergis, A., et al. Evaluación del valor pronóstico de la relación neutrófilos/linfocitos en cáncer de mama de subtipos agresivos. Rev Méd Chile, 2016, 144 (6): 691-6. https://doi.org/10.4067/S0034-98872016000600001

Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., Hadary, A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005, 93 (5): 552–555. https://doi.org/10.1038/sj.bjc.6602738

Witzel, I., Laakmann, E., Weide, R., Neunhoffer T., Park-Simon, T., Schmidt, M., et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. European Journal of Cancer. 2018, 102: 1-9. https://doi.org/10.1016/j.ejca.2018.07.004187